MONTREAL, June 18 /CNW/ - The Regie d'Assurance Maladie du Quebec (RAMQ) recently advised Pfizer that they are examining all pharmaceutical card programs in Quebec. In light of this they have sent us a formal request dated June 16, 2010 to temporarily suspend the Lipitor Continuity Card Program. As part of our ongoing collaboration with the RAMQ, we have made the decision to temporarily suspend the distribution of the Lipitor Continuity Card in Quebec while they complete their analysis.
Card programs are not a new practice in Quebec. The Lipitor Continuity Card Program is one of several card programs currently active in the province. These types of programs support patients' choice to remain on brand name pharmaceuticals, at no additional cost to them versus using the generic, if that is their preference following discussion with their healthcare provider.
Pfizer is committed to working closely with RAMQ and will update patients affected by changes to the card program, and their healthcare professionals, as appropriate.
About Pfizer Canada
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Canada's commitment to helping Canadians live happier, healthier and longer lives extends beyond medication. To learn more about Pfizer Canada's More Than Medication philosophy and programs, visit morethanmedication.ca.
These press releases were issued in Canada and are intended as reference information for Canadians. The information contained in each press release was accurate at the time of issuance, and Pfizer Canada assumes no responsibility for updating the information to reflect subsequent developments.
SOURCE Pfizer Canada Inc.
For further information: For further information: 1-866-9Pfizer (1-866-973-4937)